News
-
-
PRESS RELEASE
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Jaguar Health's Canalevia-CA1 drug receives FDA conditional approval for chemotherapy-induced diarrhea treatment in dogs, making it the first approved treatment for this condition -
-
PRESS RELEASE
New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones
Jaguar Health, Inc. announces near-term activities including Gelclair launch and crofelemer trials for rare diseases. Includes Lisa Conte interview details -
-
PRESS RELEASE
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Jaguar Health, Inc. announces issuance of new patent for crofelemer to treat rare diseases like SBS and MVID, enhancing IP protection. Independent studies supported in US, EU, and MENA regions -
-
PRESS RELEASE
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
Jaguar Health announces Eduardo Zimmer as 2024 Blas Frangione Early Career Achievement Award recipient for work with Magdalena Biosciences on plant-based mental health medicines -
-
PRESS RELEASE
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
Jaguar Health plans crofelemer approval pathway for breast and lung cancer based on phase 3 results. Join the investor webcast on August 13, 2024, for financial & corporate updates
